Single-Ascending-Dose Safety and Tolerability Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS).
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2014
At a glance
- Drugs NP-001 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Biomarker
- 30 Nov 2010 Top-line results were reported in a Neuraltus Pharmaceuticals media release.
- 04 Oct 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 04 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.